Top Articles - Real Estate

There are many types of mortgage loans. The two basic types of amortized loans are the fixed rate mortgage (FRM) and adjustable

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

rate mortgage (ARM).

In a FRM, the interest rate, and hence monthly payment, remains fixed for the life (or term) of the loan.

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

n the U.S., the term is usually for 10, 15, 20, or 30 years. The only increase a consumer might see in their monthly payments would res

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

lt from an increase in their property taxes or insurance rates (paid using an escrow account, if they've opted to use an escrow). But p

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

ayments for principal and interest will be consistent throughout the life of the loan using an FRM. In an ARM, the interest

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

rate is fixed for a period of time, after which it will periodically (annually or monthly) adjust up or down to some market index. Comm

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

n indices in the U.S. include the Prime Rate, the London Interbank Offered Rate (LIBOR), and the Treasury Index ("T-Bill"). Other index

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

es like 11th District Cost of Funds Index, COSI, and MTA, are also available but are less popular.

Adjustable rates transfer part o

nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically

the interest rate risk from the lender to the borrower, and thus are widely used where unpredictable interest rates make fixed rat

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

loans difficult to obtain. Since the risk is transferred, lenders will usually make the initial interest rate of the ARM's note anywhe

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

e from 0.5% to 2% lower than the average 30-year fixed rate. In most scenarios, the savings from an ARM outweigh its risks, making

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

them an attractive option for people who are planning to keep a mortgage for ten years or less.

Additionally, lenders rely on

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

redit reports and credit scores derived from them. The higher the score, the more creditworthy the borrower is assumed to be. Favorable

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

interest rates are offered to buyers with high scores. Lower scores indicate higher risk to the lender, and lenders require higher inte

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

rest rates in such scenarios to compensate for increased risk.

A partial amortization or balloon loan is one where the amount o

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

monthly payments due are calculated (amortized) over a certain term, but the outstanding principal balance is due at some point short

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

f that term. This payment is sometimes referred to as a "balloon payment". A balloon loan can be either a Fixed or Adjustable in terms

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

of the Interest Rate. Many Second Trust mortgages use this feature. The most common way of describing a balloon loan uses the terminolo

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

y X due in Y, where X is the number of years over which the loan is amortized, and Y is the year in which the principal balance is due.

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

A contract could be written up so there would be more than one "balloon payment" required to be paid during the life of the loan.

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

Tags

Links

Top Articles - The Many Mortgage Loan Types and There Fixed Rates

Related Articles: